Inactive Instrument

Press Releases Novartis CBOE EUROPE EQUITIES

Equities

0QLR

CH0012005267

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

May. 27	Novartis: positive phase III results in C3G	CF
May. 27	Novartis: presented results for kidney disease	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	May. 25	GL
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	May. 25	GL
Amgen And Sandoz Settle Denosumab BPCIA Litigation	May. 20	AQ
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	May. 16	GL
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	May. 15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	May. 13	AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	May. 10	AQ
Novartis : enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline	May. 02	PU
Novartis : Q1 2024 impact and sustainability update	Apr. 30	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	Apr. 26	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	Apr. 24	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL
Novartis: Q1 Earnings Snapshot	Apr. 23	AQ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	Apr. 23	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	GL
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	GL
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 12	AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	Apr. 12	AQ
Novartis tender offer for MorphoSys AG commences	Apr. 11	GL